Medicine manufacturer
But no IPO – financial investor takes over Stada
A few days ago, Stada started one of the largest IPO this year. But now a new investor has been found for the company.
The pharmaceutical manufacturer Stada does not go to the stock exchange. A few days after announcing corresponding plans, the previous owners presented a buyer for the majority at the company. According to its own announcement of Monday, the new majority investor will become the London investment company Capvest Partners. The previous shareholders Bain Capital and Cinven remain on board with a minority, as they announced themselves.
Stada boss Peter Goldschmidt had promised a IPO for autumn last week. Previous plans had been postponed due to violent stock exchange fluctuations in spring.
Companies worth ten billion euros
The parties did not provide any information at the purchase price. A company value of around ten billion Euo was adopted for the IPO. Stada, based in Bad Vilbel in Hesse, produces the Lawstad Grippostad and the Silomat cough juice. The conclusion is subject to official permits and is expected for the first half of 2026.
Previous investors on board since 2017
Bain Capital and Cinven had most recently bought the pharmaceutical manufacturer with around 11,600 employees in 2017 for 5.3 billion euros worldwide and then took it off the stock exchange.
In the first half of 2025, Stada benefited from growing businesses, especially from special medication. In the case of over-the-counter medicines that suffered from a weak cold season and imitators (generics), Stada, on the other hand, could not grow little. Overall, sales of a currency adjusted by six percent to a good 2.1 billion euros and the adjusted profit before interest, taxes and depreciation (EBITDA) rose five percent to 481 million euros.
Stada had also grown through a series of takeovers in recent years, but has accumulated around 5.7 billion euros in debt. In order to become more attractive to investors, the company had split off its Russian business – it was considered a burden on the sales plans.
dpa
Source: Stern
